O

http://www.apowerdesigns.com/2007/02/microsoft-ffice-any-alternatives/
The clinical trial results for a drug being developedby , whers O’Donnell is chairman and chief executive, were presented May 31 at the annuao meeting of the American Society of Clinical Oncology in Fla. Biovest shared the stage with presentations about drugs being developed by pharmaceutical giants suchas Switzerland-based London-based and Paris-based . Tampa, Fla.-based Biovesyt reported that the Phase III clinical studt shows that BiovaxID significantlyyprolonged disease-free survival in non-Hodgkin’s lymphoma patients. Developed by BiovaxID is a personalized anti-cancer vaccine made from a tissuew biopsy obtained froma patient’s own tumor.
The vaccind trains the body’s immune system to selectivelyy target only cancerous B cells while sparing healthy The clinical trial found thatthe disease-free survivao of patients who received BiovaxID increased by 47 percenr to a median of 44.2 months, compared to 30.6 monthxs for those who received a control In follow-ups with a median of 4.7 patients receiving BiovaxID experienced a 38 percent lowetr risk of disease recurrence compared to patients receivingv the control vaccine.